Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03676959
Other study ID # NTL-LEES-2017-02
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date August 16, 2018
Est. completion date October 15, 2022

Study information

Verified date May 2021
Source Lee's Pharmaceutical Limited
Contact lingying Wu, M.D
Phone 13910865483
Email wulingying@csco.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1, open-label, dose-escalation, and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics(PK) of ZKAB001 (a fully human monoclonal antibody targeting the Programmed Death - Ligand 1 (PD-L1) membrane receptor on T lymphocytes and other cells of the immune system) administered every 14 days in subjects with recurrent or metastatic cervical cancer.


Description:

The study will consist of 4 periods: Screening (up to 28 days), Lead-in period (Day -28), Treatment (up to 24 cycles or 1 year, whichever occurs first), and Follow-up (up to 1 year). There will be a lead-in period on Day -28 for each dose escalation cohort in which the single-dose pharmacokinetics of ZKAB001 will be characterized prior to initiation of continuous dosing in the first cycle of treatment. The lead-in period duration, PK time-points, doses and/or regimens used in subsequent cohorts may be modified based on the exposure (AUC) observed during the lead-in period (although the number of PK samples will not be increased). Treatment of continuous dosing is up to 24 cycles or 1 year, until as per investigator's opinion, subjects experience disease progression (evaluated by RECIST 1.1 and immune-related response criteria irRECIST), no clinical benefit, or intolerable toxicity. If investigators suspect subjects experience pseudoprogression or has evidence to prove "mixed response", subjects can continue to accept treatment as investigator decided. The study was divided into two stages. After the recommended phase II dose (RP2D) is determined in the first stage, the sample size will be amplified with RP2D in the second stage. When a total of 15 cases are included in the two stages, an interim analysis will be conducted to decide whether to expand the total number of cases to 60 based on the results of the analysis. If more than 2 cases of response will be observed in 15 cervical cancer subjects, 45 cases (with a total sample size of 60 cases) could be included to further observe the safety and efficacy.


Recruitment information / eligibility

Status Recruiting
Enrollment 101
Est. completion date October 15, 2022
Est. primary completion date May 15, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. The subject voluntarily gives written informed consent to participate in the study. 2. Female subjects aged=18 years. 3. Recurrent or metastatic cervical cancer was diagnosed by histopathology or cytology and received first-line platinum-containing regimens that failed or could not be tolerated. The definition of first-line failure: progress during adjuvant therapy or within 6 months after the end of treatment, and the first progress after palliative treatment. 4. Based on RECIST1.1, imaging evaluation confirmed that there was at least one measurable disease. 5. Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1, with estimated life expectancy of at least 3 months. 6. Adequate blood routine, hepatic and renal function: 1) Absolute neutrophil count(ANC)=109/L 2) Platelets =100x109/L 3) Hemoglobin =9g/dL 4) Serum albumin =2.8g/dL 5) Bilirubin =1.5x Upper limit of normal(ULN) 6) ALT and AST =1.5xULN, if If liver metastases are present, alanine transaminase(ALT) and aspartate transaminase(AST) should be =5xULN 7) Creatinine clearance rate =50ml/min (Cockcroft-Gault equation) 7.Female reproductive subjects should take effective contraception during the study period and within 3 months after the study treatment period. The serum or urine human chorionic gonadotropin (HCG)examination must be negative within 7 days before the subject is enrolled. Exclusion Criteria: 1. There are known active or suspected autoimmune diseases. Those who are in a stable state and do not need systemic immunosuppressive therapy can be included. 2. Patients are using immunosuppressive agents, or systemic, or absorbable topical corticosteroid medications to achieve immunosuppressive purposes (doses >10mg/day prednisone or equivalent), which is ongoing 2 weeks before enrollment. 3. Have received any form of organ transplantation, including allogeneic stem cell transplantation. 4. Known allergy to macromolecular protein inhibitors or any of the components of ZKAB001. 5. Suffering from other malignant tumors other than this diseases in 5 years except for skin basal cell and squamous cell carcinoma. 6. Central nervous system metastases with clinical symptoms (such as cerebral edema and brain metastases requiring corticosteroid intervention). Previous treatment with brain or meningeal metastasis, such as clinical stabilization (MRI) less than 2 months, or systemic corticosteroid (dose >10mg/day prednisone or equivalent) less than 2 weeks. 7. Patients with clinical symptoms or diseases of the heart that cannot be well controlled, such as heart failure above New York Heart Association ( NYHA ) 2 grade, unstable angina pectoris, myocardial infarction in 1 year, and clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention, have left ventricular ejection fraction < 50% at rest in the ultrasound cardiogram. 8. Patients who had received radiotherapy, chemotherapy, surgery or molecular targeted therapy before, were given less than 4 weeks. 9. Within 14 days before the first use of the drug, any active infection requiring systematic anti-infective treatment. 10. Human immunodeficiency virus (HIV) positive, untreated active hepatitis (hepatitis B surface antigen positive and peripheral blood HBV-DNA titer = 500IU/ml or positive copy number detected by the research center; hepatitis C virus antibody positive) 11. There is a history of active pulmonary tuberculosis within 1 year before entering the group. 12. The patient is participating in other clinical studies or is less than 1 month away from the end of the previous clinical study. 13. Patients may need to receive other systemic cancer treatment during study period. 14. Received blood transfusion and hematopoietic stimulating factors, such as colony stimulating factor, erythropoietin, thrombopoietin, etc., within 14 days before screening. 15. Prior therapy with an anti-PD 1, anti-PD L1, or anti-CTLA-4 (Cytotoxic T lymphocyte Antigen-4) antibody (or any other agents that target immunoregulatory receptor). 16. Subjects who received live vaccine within 4 weeks before screening. 17. History of mental drug abuse, alcohol abuse or drug abuse. 18. Pregnant or lactating women. 19. Any mental condition that prevents the understanding or provision of an informed consent. 20. It is determined by the investigator that the patient has other factors that may lead to the termination of the study, such as other serious diseases or serious laboratory test abnormalities or other factors that may affect the safety of the patients, family or social factors that may affect the study data and sample collection.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ZKAB001 5mg/kg
5mg/kg/times bi-week IV administration of ZKAB001
ZKAB001 10mg/kg
10mg/kg/times bi-week IV administration of ZKAB001
ZKAB001 15mg/kg
15mg/kg/times bi-week IV administration of ZKAB001

Locations

Country Name City State
China Chinese Academy of Medical Sciences and Peking Union Medical College Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Lee's Pharmaceutical Limited

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary RP2D Recommended phase II dose. 28 days after first dose
Primary Objective response rate The proportion of subjects who achieved the best objective response rate (PR or CR). 2 years
Primary Tolerance Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 2 years
Secondary Effect of ZKAB001 on T cell function and cytokine expression The response of CD4+ and CD8+ cells to tumor at baseline and after each administration will be detected by flow cytometry. through study completion, an average of 2 years
Secondary The number of subjects presenting detectable anti drug antibodies (ADAs) To evaluated the number of subjects presenting detectable anti drug antibodies (ADAs). through study completion, an average of 2 years
Secondary Receptor occupancy Monocytes will be isolated from peripheral blood before each cycle of administration, and the receptor occupancy of PD-L1 on CD3+T cells will be determined. through study completion, an average of 2 years
Secondary PD-L1 expression Detection of PD-L1 expression in tumor tissues. through study completion, an average of 2 years
Secondary progression free survival(PFS) Evaluate the PFS of the study population through study completion, an average of 2 years
Secondary overall survival Evaluate the OS of the study population through study completion, an average of 2 years
Secondary duration of response Evaluate the DOR of the study population through study completion, an average of 2 years
Secondary best of response Evaluate the BOR of the study population through study completion, an average of 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A